Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Cytarabine with Arsenic Trioxide vs Low-Dose Cytarabine Alone in Elderly AML
NCT00513305Phase 3Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Oct 2007
- Primary completion
- Jul 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of arsenic trioxide in acute myeloid leukemia (AML), sponsored by Cephalon, Inc.. Started Oct 2007; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00513305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00513305.